Invasive pulmonary aspergillosis is associated with adverse clinical outcomes in critically ill patients receiving veno-venous extracorporeal membrane oxygenation

被引:0
|
作者
I. Rodriguez-Goncer
S. Thomas
P. Foden
M. D. Richardson
A. Ashworth
J. Barker
C. G. Geraghty
E. G. Muldoon
T. W. Felton
机构
[1] Manchester University NHS Foundation Trust,Infectious Diseases Department, Wythenshawe Hospital
[2] Manchester University NHS Foundation Trust,Microbiology Department, Wythenshawe Hospital
[3] Manchester University NHS Foundation Trust,Medical Statistics Department, Wythenshawe Hospital
[4] Manchester University NHS Foundation Trust,Mycology Reference Centre, Wythenshawe Hospital
[5] The University of Manchester,Division of Infection, Immunity and Respiratory Medicine
[6] Manchester Academic Health Science Centre,Cardiothoracic Critical Care Unit, Wythenshawe Hospital
[7] Manchester University NHS Foundation Trust,Manchester Medical School
[8] University of Manchester,Infectious Diseases Department
[9] Mater Misericordiae University Hospital,Acute Intensive Care Unit, Wythenshawe Hospital
[10] Manchester University NHS Foundation Trust,undefined
来源
European Journal of Clinical Microbiology & Infectious Diseases | 2018年 / 37卷
关键词
ECMO; Galactomannan; Voriconazole; Outcome;
D O I
暂无
中图分类号
学科分类号
摘要
To identify the incidence, risk factors and impact on long-term survival of invasive pulmonary aspergillosis (IPA) and Aspergillus colonisation in patients receiving vv-extracorporeal membrane oxygenation (ECMO). A retrospective evaluation was performed of patients receiving vv-ECMO at a tertiary hospital in Manchester (UK) between January 2012 and December 2016. Data collected included epidemiological data, microbiological cultures, radiographic findings and outcomes. Cases were classified as proven IPA, putative IPA or Aspergillus colonisation according to a validated clinical algorithm. One hundred thirty-four patients were supported with vv-ECMO, median age of 45.5 years (range 16.4–73.4). Ten (7%) patients had putative IPA and nine (7%) had Aspergillus colonisation. Half of the patients with putative IPA lacked classical host risk factors for IPA. The median number of days on ECMO prior to Aspergillus isolation was 5 days. Immunosuppression and influenza A infection were significantly associated with developing IPA in a logistic regression model. Cox regression model demonstrates a three times greater hazard of death associated with IPA. Overall 6-month mortality rate was 38%. Patients with putative IPA and colonised patients had a 6-month mortality rate of 80 and 11%, respectively. Immunosuppression and influenza A infection are independent risk factors for IPA. IPA, but not Aspergillus colonisation, is associated with high long-term mortality in patients supported with vv-ECMO.
引用
收藏
页码:1251 / 1257
页数:6
相关论文
共 50 条
  • [21] Veno-venous extracorporeal membrane oxygenation in severe acute respiratory failure
    Offer, J.
    Sampson, C.
    Charlton, M.
    BJA EDUCATION, 2024, 24 (04) : 138 - 144
  • [22] Intoxication and overdose should not preclude veno-venous extracorporeal membrane oxygenation
    Radowsky, Jason S.
    Mazzeffi, Michael M.
    Deatrick, K. Barry
    Galvagno, Samuel M.
    Parker, Brandon M.
    Tabatabai, Ali
    Madathil, Ronson J.
    Kaczorowski, David J.
    Rabinowitz, Ronald P.
    Herr, Daniel L.
    Scalea, Thomas
    Menaker, Jay
    PERFUSION-UK, 2021, 36 (08): : 839 - 844
  • [23] Awake veno-venous extracorporeal membrane oxygenation: practical aspects and considerations
    Paternoster, Gianluca
    Bertini, Pietro
    Sangalli, Fabio
    Scolletta, Sabino
    MINERVA ANESTESIOLOGICA, 2024, : 92 - 100
  • [24] Veno-venous extracorporeal membrane oxygenation support of pulmonary insufficiency using Avalon Elite® cannula in pediatric patients
    Fujita, Satoshi
    Ushijima, Tomoki
    Shinohara, Gen
    Oda, Shinichiro
    Shiose, Akira
    JOURNAL OF ARTIFICIAL ORGANS, 2024, 27 (03) : 301 - 305
  • [25] In Vivo Suction Pressures of Venous Cannulas During Veno-venous Extracorporeal Membrane Oxygenation
    Robak, Oliver
    Grafeneder-Weissteiner, Theresa
    Schellongowski, Peter
    Bojic, Andja
    Paschen, Christopher
    Hermann, Alexander
    Staudinger, Thomas
    ASAIO JOURNAL, 2022, 68 (11) : 1372 - 1378
  • [26] Long-term outcomes of adults with acute respiratory failure treated with veno-venous extracorporeal membrane oxygenation
    Gray, Emma L.
    Forrest, Paul
    Southwood, Timothy J.
    Totaro, Richard J.
    Plunkett, Brian T.
    Torzillo, Paul J.
    ANAESTHESIA AND INTENSIVE CARE, 2021, 49 (06) : 477 - 485
  • [27] An External Validation of Scoring Systems in Mortality Prediction in Veno-Venous Extracorporeal Membrane Oxygenation
    Man, Man-Yee
    Shum, Hoi-Ping
    Lam, Sin-Man
    Yu, Judianna S. Y.
    King, Bobby H. S.
    Yan, Wing-Wa
    ASAIO JOURNAL, 2022, 68 (02) : 255 - 261
  • [28] Lack of association between body weight and mortality in patients on veno-venous extracorporeal membrane oxygenation
    Al-Soufi, Suhel
    Buscher, Hergen
    Nguyen Dinh Nguyen
    Rycus, Peter
    Nair, Priya
    INTENSIVE CARE MEDICINE, 2013, 39 (11) : 1995 - 2002
  • [29] Single Center Experience With Veno-Venous Extracorporeal Membrane Oxygenation in Patients With Traumatic Brain Injury
    Parker, Brandon M.
    Menaker, Jay
    Berry, Cherisse D.
    Tesoreiero, Ronald B.
    O'Connor, James V.
    Stein, Deborah M.
    Scalea, Thomas M.
    AMERICAN SURGEON, 2021, 87 (06) : 949 - 953
  • [30] Weaning from veno-venous extracorporeal membrane oxygenation: how I do it
    Broman, Lars M.
    Malfertheiner, Maximilian V.
    Montisci, Andrea
    Pappalardo, Federico
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S692 - S697